RALEIGH, N.C., Oct. 21, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today announced the appointment of Ernest R. De Paolantonio, CPA MBA as Chief Financial Officer and Corporate Secretary. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) Mr. De Paolantonio joins BDSI with over 35 years of varied financial and business experience in the pharmaceutical industry, and his skill set is intended to broaden BDSI's executive level expertise as the company continues its evolution from a research and development and outlicensing business into a commercial stage enterprise. In addition to overall responsibility for BDSI's finance function, the company expects to leverage Mr. De Paolantonio's involvement in manufacturing, supply chain and other commercialization activities, particularly as BDSI looks to finalize its commercial options for BUNAVAIL, an NDA for which is currently under review by the FDA. Similar expertise will be valuable as BDSI's moves toward completion of the Phase III program for BEMA Buprenorphine for chronic pain, which is partnered with Endo, and in exploring other business development opportunities. James A. McNulty, CPA, BDSI's current Chief Financial Officer, Treasurer and Secretary, will remain with BDSI in the new role of Senior Vice President—Finance and Treasurer. Mr. McNulty will report to Mr. De Paolantonio. Over the past five years, Mr. De Paolantonio served as the Chief Financial Officer of CorePharma, a private specialty generic company, during the period of the company's most prolific growth. While at CorePharma, Mr. De Paolantonio was directly involved in the financial and commercial strategy to establish their proprietary labeled portfolio of products. In addition, he previously served in finance and controller positions in roles of increasing responsibility at Colombia Laboratories, where he was also responsible for business development and logistics, including supply chain management for the company's first commercial product launch. Additionally, he served in various financial and controller positions at Taro Pharmaceuticals, Watson Pharmaceuticals and Danbury Pharmaceutical. Mr. De Paolantonio began his career in finance at GlaxoSmithKline, where he spent over 17 years.